Bluejay Therapeutics

About:

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Website: http://bluejaytx.com

Top Investors: Novo Holdings, RA Capital Management, Wellington Management, RiverVest, Yonjin Venture

Description:

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Total Funding Amount:

$242M

Headquarters Location:

San Mateo, California, United States

Founded Date:

2019-01-01

Founders:

Keting Chu

Number of Employees:

11-50

Last Funding Date:

2024-05-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai